Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
Time to take the L here lads, its a shame
no there isn't
Guessed? Was it not quite obvious? I invested here 2 years ago and yes, I did make a slight loss overall. The only reason my tune changed because it was so obvious to see that this is not going anywhere anytime soon. Yes we know the drug works in a subset of patients, but to prove this on a larger scale, we need a new platform study which will take years. Regarding activ-2, its very obvious that this wasn't going to proceed given the changing landscape of the virus. I do think if you average is below 30p and you are willing to wait 2 years, then this will most certainly come good. But I am sick of the vermin on this board ramping this share convincing others who are more naive to invest into something that isn't going "back to 1.50" anytime soon.
The rampers got excited last week with the rise following the update. I told you activ-2 wasn't going to go ahead for many of the same reasons detailed in the RNS. You laughed and told me leave the board.
Remove the rose tinted glasses fgs!!!!
I can't beleive Dan the man is back again!
its confirmed it has been paused, there is still a huge chance that the whole trial will be cancelled. Even if this trial continues, we are now looking at 18 months until data. We never had doubts that SNG001 would work against omicron. Be OBJECTIVE
Be objective about this RNS. Remove the rose tinted glasses. Activ-2 is on pause, which is horrible news as that was the "near term" (12 month) SP accelerator. Yes we are potent against omicron, we never thought we weren't. Yes there were some trends in sprinter which needs a PLATFORM study. Nothing is going to happen for at least 18 months now.
why on earth are people banking on activ-2 which hasn't even started recruiting yet. Covid will be irrelevant by the time it reads out. AIM is all about sentiment, and there won't be any. What WOULD be interesting is a respiratory trial that looks at several viral infections and the effect of sng001 on them.